A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with ...

BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative drug combination that overcomes ...

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors ...

Dawe, PhD, as Scientific Advisor, Neuropharmacology & Translational Neuroscience, and Tomi K. Sawyer, PhD, as Strategic ...

From a design perspective, it is difficult to truly integrate a data centre into a mixed-use campus — security needs to be ...

On April 9, 2026, Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb focused on the discovery and development of T-cell engager therapies for solid tumors. 1 ...

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen ...

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

The Board of Directors of John Marshall Bancorp, Inc. (the "Company") , the parent company of John Marshall Bank (the "Bank"), is pleased to report that the investment banking firm Raymond James & ...

Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by th ...

A hybrid planning application to transform the former GSK headquarters at 980 Great West Road in Brentford has been approved, ...